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ABSTRACT
Introduction: Clostridium difficile infection
(CDI) is a common cause of nosocomial
diarrhea. Metronidazole and vancomycin are
the primary treatment options for CDI, but
increasing rates of antimicrobial resistance and
severe, refractory disease have prompted the
need for alternative agents. Tigecycline has
previously demonstrated favorable in vitro
activity against C. difficile isolates, but clinical
data on its use in the treatment of CDI are
severely lacking. The objective of this study was
to describe our experience using tigecycline in
the treatment of severe and severe complicated
CDI.
Methods: This was a retrospective case series of
hospitalized patients with severe and severe
complicated CDI who were treated with
tigecycline. Disease severity assessments were
determined according to current practice
guidelines. Diagnosis of toxigenic CDI was
confirmed by polymerase chain reaction and
patients were excluded if they received
tigecycline for\48 h. Data were collected by
review of the electronic medical record. The
primary outcome was clinical cure. Secondary
outcomes were sustained response, hospital
mortality, and 28-day all-cause mortality.
Results: A total of 7 cases of severe and
complicated CDI were reviewed. Intravenous
tigecycline administered as a 100-mg loading
dose followed by 50 mg twice daily resulted in
clinical cure in 85.7% (n = 6/7) of cases. The
majority of patients (n = 4/5) were treated with
the novel triple therapy combination of
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tigecycline, vancomycin, and metronidazole
and resulted in clinical cure in 80% (n = 4/5)
cases. Sustained response at 28 days was 100%
among evaluable cases (n = 5/5). Hospital
mortality did not occur in any patients, and
28-day all-cause mortality was 28.6% (n = 2/7).
Conclusion: Tigecycline appears to be a
reasonable addition to the therapeutic regimen
in the treatment of severe or complicated CDI,
including cases that are refractory to standard
therapy. A prospective clinical trial confirming
these observational findings is warranted.
Keywords: Clostridium difficile; Combination
drug therapy; Tigecycline
INTRODUCTION
Clostridium difficile infection (CDI) is the most
common cause of nosocomial diarrhea in adults
[1, 2]. The clinical manifestations of CDI range
from mild diarrhea to fulminant colitis and
severe sepsis, which may be life threatening [2,
3]. Metronidazole and vancomycin have been
mainstays in CDI treatment guidelines for
several decades, but increasing rates of
refractory disease have necessitated the
consideration of alternative therapies [1, 4].
According to a recent United States Centers for
Disease Control and Prevention (CDC) report,
C. difficile is one of only three pathogens to be
classified as an ‘‘urgent’’ threat to public health
due to increasing rates of antimicrobial
resistance [5]. Moreover, the emergence of the
hypervirulent NAP1/BI/PCR ribotype 027 strain
has been associated with severe, recurrent
disease that is often non-responsive to
standard therapy [6].
Metronidazole and vancomycin are still
recommended for the initial management of
CDI; however, there are no consensus
guidelines for the treatment of CDI that is
refractory to these agents [1]. Tigecycline is a
broad spectrum glycylcycline antibiotic that is
approved for use in the United States for the
treatment of complicated skin and soft tissue
infections, intra-abdominal infections, and
community-acquired pneumonia [7]. Multiple
studies have demonstrated the favorable
in vitro activity of tigecycline against C.
difficile isolates [8–10]. Additionally, tigecycline
has demonstrated a low minimum inhibitory
concentration (MIC) among multidrug-resistant
C. difficile isolates (mean MIC90 0.25 mg/L;
range B0.06–2 mg/L) relative to its achieved
fecal concentrations at standard doses (mean
concentration 6.0 mg/kg; range 3.0–14.1 mg/
kg) [8, 10, 11]. Tigecycline is excreted into the
gastrointestinal tract with limited disruption of
intestinal flora, making it an ideal candidate for
the treatment of CDI [9, 12, 13].
Despite the favorable in vitro activity profile
of tigecycline against C. difficile, there is limited
clinical data describing its use in the
management of CDI. There are limited case
reports of the use of tigecycline for the
treatment of CDI described in the literature
[14–17]. Therefore, the objective of this study
was to detail our experience using tigecycline
for the treatment of CDI.
METHODS
Patients
This was a retrospective case series of
hospitalized patients at the University of
Kansas Hospital, a tertiary care academic
medical center. All adult patients who were
treated with tigecycline for CDI from January
2007 through July 2013 were eligible for
inclusion in this study. Diagnosis of CDI was
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confirmed by the presence of diarrhea with C3
unformed stools for 2 consecutive days plus
detection of toxigenic C. difficile in the stool by
polymerase chain reaction (PCR). Patients who
received tigecycline for less than 48 h were
excluded from analysis. Clinical data were
collected by retrospective review of the
electronic medical record using a standardized
data collection form. Variables collected
included: patient demographics, comorbidities,
laboratory data, microbiological data, vital
signs, antimicrobial treatment data, and
preceding antimicrobial treatment
information. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008. Due to the
retrospective nature of this study, a waiver of
informed consent was obtained and approved
by the University of Kansas Medical Center
human subjects committee.
Disease Severity Assessments
All cases were classified according to CDI disease
severity upon detection of C. difficile toxin and
initiation of tigecycline therapy according to
current practice guidelines [1]. Severe disease
was defined as a white blood cell (WBC) count
of[15,000/lL or a rise in serum creatinine
150% of the premorbid level [1]. Severe
complicated disease was defined as the
presence of: (i) C. difficile sepsis; (ii) ileus; or
(iii) toxic megacolon [1]. Clostridium difficile
sepsis was defined as confirmed CDI plus the
presence of at least two of the following
systemic inflammatory response syndrome
(SIRS) criteria: (i) temperature[38 C
or\36 C; (ii) heart rate[90 beats per minute;
(iii) respiratory rate[20 breaths per minute or
PaCO2\32 mmHg; or (iv) WBC[12,000/lL
or\4,000/lL or[10% bands [18]. Additionally,
an ATLAS score was computed for each patient
as described by Miller et al. [19]. ATLAS is a
validated scoring system used to predict
response to antibiotic treatment against CDI
[19]. In general, the higher the ATLAS score, the
lower the observed clinical cure rate [19]. To
estimate individual comorbidity burden, the
Charlson comorbidity index (CCI) was
computed for each patient [20].
Outcome Measures
The primary outcome of this study was clinical
cure, defined by the resolution of the following
signs and symptoms of CDI maintained for the
subsequent duration of tigecycline therapy
without further addition of an anti-CDI agent:
(i) diarrhea (C3 unformed stools for 2
consecutive days); (ii) fever[37.5 C; (iii) WBC
count[12,000/lL; and (iv) abdominal pain.
Clinical failure was defined as persistence of
CDI symptoms or the need for additional anti-
CDI therapy due to perceived failure of
tigecycline therapy. Secondary outcomes
included sustained response, hospital
mortality, and 28-day all-cause mortality.
Sustained response was defined as clinical cure
without subsequent recurrence in 28 days
following treatment with tigecycline. Data
were also collected on side effects attributed to
tigecycline use by a treating physician.
RESULTS
A total of 251 hospitalized patients who
received tigecycline between January 2007 and
July 2013 at our institution were screened for
inclusion in this study. Of these patients, nine
were treated with tigecycline for CDI. Two
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patients were excluded due to\48 h of
treatment with tigecycline. In both of these
cases, alternative agents for CDI were used
according to the decision of a treating
physician. A total of seven patients met study
criteria and were included in the final analysis.
Case Reports
Case 1 occurred in a 64-year-old female who was
admitted for community onset CDI. This
patient had multiple risk factors for CDI,
including recent antibiotic use (meropenem
and vancomycin for pneumonia, and
levofloxacin for chronic leukopenia) and
immunosuppression. She was initially
leukopenic secondary to end-stage liver disease
awaiting transplantation with mild CDI (WBC
600/lL, serum creatinine 138% relative to
baseline). She was treated with intravenous
metronidazole 500 mg three times daily for
CDI starting on hospital day 1. On hospital
day 2, follow-up PCR for toxigenic C. difficile
remained positive. Her early hospital course was
unremarkable; however, she developed ileus,
nausea, and vomiting on hospital day 4 and her
CDI had progressed from mild to a severe
complicated case. The patient was transferred
to the intensive care unit (ICU) and oral
vancomycin 125 mg four times daily was
added to the regimen. On hospital day 6, the
patient’s ileus remained unresolved, her serum
creatinine level increased to 188% of the
premorbid level and she developed severe
abdominal pain. Due to the concerns for
limited effectiveness of oral vancomycin in the
setting of ileus, intravenous tigecycline was
added to the regimen on hospital day 6 as a
100-mg loading dose followed by 50-mg doses
twice daily. This patient was treated with a
combination of intravenous tigecycline, oral
vancomycin, and intravenous metronidazole
for 10 days. No side effects of tigecycline
therapy were noted in the electronic medical
record. Follow-up PCR for toxigenic C. difficile
was negative at the end of treatment. This
patient was at high risk of recurrence due to her
chronic antibiotic use and pancytopenia.
Therefore, she was discharged to a long-term
care facility where she completed a 30-day
vancomycin taper. She had no subsequent
recurrence of CDI on record.
Case 2 occurred in a 46-year-old male who
was admitted to the ICU with severe diarrhea
and septic shock requiring 13 L fluid
resuscitation and vasopressors. The patient
presented with severe leukocytosis (WBC
35,400/lL) and renal impairment (serum
creatinine increased 166% of the premorbid
level). This patient had a number of risk factors
for CDI, including admission from a long-term
care facility and multiple prior antibiotic use
(see Table 1 for full listing). He was treated
initially with oral metronidazole 500 mg three
times daily. Oral metronidazole was switched to
intravenous and oral vancomycin 125 mg four
times daily was added on hospital day 2 upon
detection of toxigenic C. difficile. At this point,
the patient was intubated due to decreasing
respiratory function and pulmonary edema. He
also had other symptoms of severe complicated
CDI, included nausea and vomiting, abdominal
pain, colonic wall thickening, and ascites. Oral
vancomycin was changed to rectal vancomycin
500 mg four times daily on hospital day 3 due to
the development of paralytic ileus. This
regimen continued through hospital day 7,
with fever, ileus, and abdominal pain
resolving. On hospital day 8, the patient again
developed diarrhea with abdominal pain and
persisting leukocytosis (WBC 24,300/lL). Due
to these non-resolving symptoms and the
severity of the patient’s condition, intravenous
tigecycline was added on hospital day 8 as a
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100-mg loading dose followed by 50 mg twice
daily. Clinical cure was achieved after 8 days of
treatment with tigecycline, rectal vancomycin,
and intravenous metronidazole. Due to the
high risk of recurrence, the patient completed
a vancomycin taper upon discharge to a long-
term care facility. There was no documented
recurrence of CDI on record.
Case 3 occurred in a 38-year-old male who
was initially admitted due to acute hypoxic
respiratory failure and necrotizing pancreatitis.
For this infection, he was treated with
piperacillin–tazobactam, which was switched
to ampicillin–sulbactam after 10 days by the
consulting infectious diseases specialist. On
hospital day 25, the patient started developing
copious diarrhea ([15 loose stools per day),
fever (38.4 C), and leukocytosis (WBC 13,500/
lL) consistent with C. difficile sepsis and severe
complicated CDI. The patient’s serum
creatinine levels increased 143% relative to
baseline. Upon confirmation of CDI on
hospital day 26, intravenous metronidazole
500 mg three times daily was initiated.
Tigecycline was added on hospital day 27 for
dual coverage of enterococcal pancreatitis and
C. difficile. Oral vancomycin 250 mg four times
daily was also added at this time and
metronidazole was discontinued by decision of
the treating physician. Fever and leukocytosis
subsided and diarrhea improved on 8 days of
combination therapy with tigecycline and oral
vancomycin. There was no recurrence of CDI on
record.
Case 4 occurred in an 80-year-old female
who was admitted due to increasing fatigue and
copious diarrhea consistent with community
onset CDI. Her risk factors for CDI included
advanced age and recent antibiotic use
(vancomycin, levofloxacin, and piperacillin–
tazobactam). This patient’s initial severity of
illness was mild (WBC 9,100/lL, serum
creatinine 116% of the premorbid level) and
she was treated with oral metronidazole 500 mg
three times daily beginning on hospital day 1.
After 3 days of metronidazole treatment, her
abdominal pain had improved, but the diarrhea
persisted and her WBC began trending upward
(16,500/lL). On hospital day 4, the patient
developed septic shock secondary to CDI. As her
CDI had progressed to a severe complicated
case, intravenous tigecycline and vancomycin
250 mg four times daily were added. Tigecycline
was given as a 100-mg loading dose followed by
50 mg twice daily. The patient was treated
successfully with 6 days of triple therapy with
tigecycline, vancomycin, and metronidazole.
Due to the high risk of CDI recurrence in this
patient, a vancomycin taper was completed.
The patient was discharged to home and had no
CDI recurrence within 28 days of follow-up.
Case 5 occurred in a 68-year-old male who
was admitted to the hospital for febrile
neutropenia secondary to pre-B cell acute
lymphoblastic leukemia. This patient had
multiple risk factors for CDI, including
advanced age, hematologic malignancy,
multiple prior antibiotic use (trimethoprim–
sulfamethoxazole, levofloxacin, linezolid, and
cefepime), prior chemotherapy use, and
hospitalization. On hospital day 6, the patient
developed acute respiratory distress and severe
sepsis (4/4 SIRS criteria). On hospital day 7, the
patient developed diarrhea and C. difficile toxin
was detected. This case was classified as severe
complicated CDI and treated initially with two
days of intravenous metronidazole 500 mg
three times daily and oral vancomycin 125 mg
four times daily. On hospital day 9, tigecycline
was added due to persisting diarrhea ([800 mL
liquid stool) and fever (38.2 C). The patient’s
fever resolved on hospital day 11, diarrhea
resolved on hospital day 14, and clinical cure
was achieved. Triple therapy with tigecycline,
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vancomycin, and metronidazole was continued
for a total of 21 days due to concerns for
recurrence in the context of the patient’s
pancytopenia. At this time, the patient was
switched to palliative care due to underlying
cancer with a poor overall prognosis. He
tolerated treatment with tigecycline well and
no side effects were reported. The patient was
discharged home to hospice with no further
CDI treatment. Sustained response was
unevaluable due to death within 28 days of
tigecycline completion.
Case 6 occurred in an 84-year-old female
admitted from a nursing home with altered
mental status, leukocytosis (WBC 19,300/lL),
and acute kidney failure (serum creatinine
increased 497% relative to baseline). The
patient was admitted to the ICU with severe
complicated CDI with septic shock. Intravenous
metronidazole 500 mg three times daily and
oral vancomycin 125 mg four times daily were
started on hospital day 1. The patient’s diarrhea
and leukocytosis persisted (WBC 41,200/lL) and
intravenous tigecycline was added on hospital
day 7 as a 100-mg loading dose followed by
50 mg twice daily. She was treated with
combination tigecycline, vancomycin, and
metronidazole for 3 days. The patient’s
diarrhea resolved and her WBC decreased yet
remained elevated (WBC 33,600/lL).
Tigecycline was discontinued per the family’s
decision to switch her to oral antibiotics for
discharge to hospice. This patient was classified
as clinical failure due to non-resolving
leukocytosis and sustained response was
unevaluable due to the lack of clinical cure.
No side effects associated with tigecycline use
were noted in the electronic medical record.
Case 7 occurred in a 73-year-old female who
was initially admitted due to pneumonia and
acute kidney injury. The patient was treated
empirically with vancomycin, levofloxacin, and
piperacillin-tazobactam. On hospital day 3, the
patient developed copious diarrhea, nausea,
leukocytosis (WBC 20,000/lL) and serum
creatinine increased 151% of the premorbid
level. Clostridium difficile toxin was detected and
oral metronidazole 500 mg three times daily
was initiated. Tigecycline was added on hospital
day 5 based on recommendations by the
consulting infectious diseases specialist.
Tigecycline was initiated instead of
vancomycin due to the additional coverage of
the patient’s concomitant vancomycin-resistant
enterococcal urinary tract infection. The patient
was successfully treated with 4 days of
combination therapy with tigecycline and
metronidazole with resolution of all CDI
symptoms. No side effects attributed to
tigecycline use were noted, and she had no
documented CDI recurrence on record.
DISCUSSION
In this case series, we describe the successful use
of tigecycline combination therapy for the
treatment of severe and severe complicated
CDI. A summary of patient characteristics,
selected risk factors, antimicrobial treatments,
and clinical outcomes is presented in Table 1.
The majority of patients [85.7% (n = 6/7)] were
classified as having severe complicated CDI
upon initiation of tigecycline therapy. In all of
the included cases, tigecycline was administered
intravenously as a 100-mg loading dose,
followed by 50 mg twice daily for the
subsequent duration of treatment. The length
of tigecycline therapy varied considerably
(range 3–21 days; median, 8 days; interquartile
range 4–11 days). The majority of cases [71.4%
(n = 5/7)] featured triple therapy with
tigecycline, vancomycin, and metronidazole,
which has yet to be reported in the peer-
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reviewed literature. This combination
demonstrated a clinical cure rate of 80%
(n = 4/5). Overall, tigecycline combination
therapy resulted in clinical cure in 85.7%
(n = 6/7) of cases with no observed hospital
mortality. In general, the ATLAS scoring system
seemed to correlate well with clinical success,
with the only clinical failure observed in the
patient with the highest score. In this case,
tigecycline was discontinued prior to resolution
of symptoms due the patient’s poor overall
prognosis and decision to switch to palliative
care, not perceived treatment failure.
Oral vancomycin at a dose of 125 mg given 4
times per day is preferred for the treatment of
severe CDI [1]. Unfortunately, in cases of severe
complicated CDI where gut motility is
impaired, the efficacy of oral vancomycin is
questionable [1]. In these instances, addition
of rectal vancomycin or intravenous
metronidazole is recommended, although the
delivery of rectal vancomycin may be
insufficient and adds the risk for colonic
perforation [1]. There are currently no other
alternatives to these agents in severe and severe
complicated CDI mentioned in the current
guidelines [1]. Recent evidence indicates
fidaxomicin is non-inferior to vancomycin in
the treatment of severe CDI [21]. None of the
patients included in this study received
fidaxomicin; however, only 2 of the 7 cases
(case 5 and 6) occurred after the introduction of
fidaxomicin to the market. At the time of these
cases, data on the effectiveness of fidaxomicin
in severe CDI had not been widely
disseminated, which may explain why this
agent was not used. Of note, fidaxomicin is
only available in oral formulation, which
prevents its use in cases where intravenous
treatment is required.
Based on the data presented in this case
series, combination therapy with tigecycline
appears to be a reasonable alternative in the
treatment of severe and severe complicated
CDI, including cases that are unresponsive to
standard therapy. While it is difficult to
attribute the high clinical cure rate observed
in these cases solely to the addition of
tigecycline, all of the patients had unresolved
symptoms and met criteria for severe or severe
complicated CDI upon tigecycline initiation.
Several published case reports have also
described the successful use of tigecycline for
CDI, either as monotherapy or in combination
with other agents [15–17, 22]. In contrast, there
has been one published failure of tigecycline to
treat severe CDI [23]. To our knowledge, there is
no in vitro data on tigecycline combinations
against C. difficile isolates, but tigecycline alone
exhibits potent activity [8, 10]. Results from a
recent study also suggest that tigecycline can
prevent C. difficile sporulation [24].
Sustained response was observed in 100%
(n = 5/5) of evaluable cases. Because the
majority of evaluable cases [60% (n = 3/5)]
featured maintenance treatment with tapered
vancomycin, it is difficult to interpret this
finding. Nonetheless, the limited disruption of
intestinal microflora demonstrated by
tigecycline in gut models suggests that
increased recurrence with the addition of
tigecycline is unlikely [9, 12, 13, 25].
Fidaxomicin also does not significantly alter
the intestinal microbiota and as a result
decreases the risk of CDI recurrence in
comparison to vancomycin [21]. Whether
tigecycline monotherapy can also
significantly reduce the risk of CDI recurrence
compared to standard therapies deserves future
study. All of the included cases were in
patients with no previous CDI detected.
Therefore, we cannot draw any conclusions
on the usefulness of tigecycline in treating
recurrent CDI.
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The present investigation has a number of
limitations. First, this was a retrospective of case
series and is limited by the lack of a comparison
group. In 2 of the patients (cases 3 and 4),
vancomycin and tigecycline were initiated on
the same day, making any potential added
benefit from tigecycline difficult to determine.
In another case (case 7), tigecycline was added
after only 1 day of treatment with
metronidazole. Therefore, it is unclear if the
infection would have resolved without the
addition of tigecycline. Finally, C. difficile
strain typing and susceptibility testing is not
routinely performed at our institution and this
potentially informative data were not available
for any of the included cases.
Perhaps the greatest strength of this study
was the ability to capture cases of severe and
fulminant CDI, which are usually excluded
from clinical trials and experimental studies.
Observed 28-day mortality was only 28.6%
(n = 2/7), which we consider to be low relative
to the severity of illness observed. Mortality in
severe fulminant CDI is as high as 90% overall
and 75% post-colectomy [1, 3]. The basis for the
substantially lower mortality rate in the present
study is unclear. Tigecycline is a derivative of
minocycline, which has well-established anti-
inflammatory properties and has been shown to
inhibit secretion of phospholipase A2 [26, 27].
Phospholipase A2 is released by fibroblasts in
response to C. difficile toxin B and is known to
play a role in shock and organ failure in sepsis
[28]. Additionally, inhibition of phospholipase
A2 release has been shown to reduce mortality
in septic rat models [28]. Although there is
currently no data on the ability of tigecycline to
inhibit C. difficile toxin-mediated colitis and
phospholipase secretion, it is a hypothesis that
warrants further exploration. None of the
patients with fulminant disease were
considered clinically stable enough to undergo
colectomy. Therefore, tigecycline combination
therapy may be an alternative for patients in
which surgery is deemed too risky.
CONCLUSION
In summary, we describe the clinical cure of
severe and severe complicated CDI in six of seven
patients treated with tigecycline combination
therapy. Tigecycline combination therapy
appears to be an acceptable option for the
treatment of CDI, including cases of fulminant
disease that is refractory to other treatments.
Further research is needed to better characterize
the role of tigecycline in the treatment of CDI. In
particular, in vitro data on the activity of
tigecycline combinations against clinical C.
difficile isolates (including hypervirulent
strains) and replication of our findings in a
prospective clinical trial are warranted.
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